Program
sefaxersen
Its studies are mostly in Glomerulonephritis, IGA, led by Hoffmann-La Roche.
Furthest: phase 3, since Mar 22, 20231 company-led study, 1 open or runningNext primary completion: May 25, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 3since Mar 22, 2023 | Mar 22, 2023 | May 25, 2028phase 3 · NCT05797610 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6299 sefaxersen (Ionis)
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2023First study: phase 3 study in Glomerulonephritis, IGAFirst studyNCT05797610 · 459 enrolled · United States, Argentina, Australia and more
- Oct 5, 2026Primary completion moved from 2026-08-31 to 2028-05-25Date moved laterphase 3 · +21 months · NCT05797610
Ahead
- May 25, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT05797610
TargetBeta
“A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression”study text, read by Claude · the study
Other programs on CFB
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05797610Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 25, 2028 | 459 |
How it is read
Names in the registry
- “Sefaxersen (RO7434656)”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.